No fixation of price for 98 drugs identified by NPPA
NPPA had earlier identified and prepared a list of fixing the price for 98 drugs used for treating various diseases such as such as tuberculosis, cardiac conditions, anemia, malaria and infections.
However, it is now reported that the central government has not been able to fix the price these drugs due to non-availability of information.
NPPA has further informed that at present the government caps prices based on the simple formula of averaging out of all medicines in a particular therapeutic segment with sales of more than 1 per cent. Under this initiative, the government has fixed the ceiling price of 530 formulations from the list of essential medicines included in Schedule-1 of DPCO, 2013.
"NPPA prepared list of 98 medicines included in Schedule - I of DPCO, 2013 for which no information is available and prices could not be fixed/notified," National Pharmaceutical Pricing Authority said in a statement on its website.
In an earlier statement in July, NPPA had asked various stakeholders to provide related data in 30 days.
It had sought data/information about these 98 formulations from all state governments and UTs, Drug Controller General of India, drug controllers of states and UTs, IMS health, Pharma Trac and apex pharma organisations such as OPPI, IDMA, IPA, among others, and trade associations.
However, it is now reported that the central government has not been able to fix the price these drugs due to non-availability of information.
NPPA has further informed that at present the government caps prices based on the simple formula of averaging out of all medicines in a particular therapeutic segment with sales of more than 1 per cent. Under this initiative, the government has fixed the ceiling price of 530 formulations from the list of essential medicines included in Schedule-1 of DPCO, 2013.
"NPPA prepared list of 98 medicines included in Schedule - I of DPCO, 2013 for which no information is available and prices could not be fixed/notified," National Pharmaceutical Pricing Authority said in a statement on its website.
In an earlier statement in July, NPPA had asked various stakeholders to provide related data in 30 days.
It had sought data/information about these 98 formulations from all state governments and UTs, Drug Controller General of India, drug controllers of states and UTs, IMS health, Pharma Trac and apex pharma organisations such as OPPI, IDMA, IPA, among others, and trade associations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.